Eden Biodesign and Liverpool University develop new therapeutics for cancer
UK biopharmaceutical company Eden Biodesign, a leading provider of development and manufacturing services for new medicines, has been selected by the University of Liverpool to develop and manufacture monoclonal antibodies against a novel cancer antigen investigated by Dr Roger Barraclough and his research team from the School of Biological Sciences.
UK biopharmaceutical company Eden Biodesign, a leading provider of development and manufacturing services for new medicines, has been selected by the University of Liverpool to develop and manufacture monoclonal antibodies against a novel cancer antigen investigated by Dr Roger Barraclough and his research team from the School of Biological Sciences.
The project will be executed at the state-of-the-art National Biomanufacturing Centre (NBC), a £34.25m initiative developed and owned by the Northwest Regional Development Agency (NWDA). The project has been facilitated by MerseyBIO, the organisation responsible for developing the life sciences sector on Merseyside, including the commercialisation of the University's life sciences research.
"We are delighted to be providing genuine practical assistance to UK academia in developing and commercialising their discoveries," said Dr Linda Magee, NWDA biotechnology sector director and head of Bionow, who is the NBC project director. "Additionally, we are very pleased that the project has been initiated at the University of Liverpool, further highlighting the potential of the Northwest."
The £34.25m National Biomanufacturing Centre, to be officially opened later this year, is a Government-funded initiative led by the NWDA additionally funded through the European Regional Development Fund and the Department of Trade and Industry and aims to establish England's Northwest as one of the foremost biomanufacturing centres in Europe.
The centre provides the expertise and facilities to support new and existing biotechnology companies, offering product development services designed to fill in the skill and resource gaps that exist within these organisations. It also provides training in biomanufacturing and analytical sciences. There is also an Access Fund of nearly £3m, which is available to qualifying small to medium companies and academic groups in the biotechnology sector to assist them in purchasing development and clinical manufacturing services from the Centre.